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Abstract
El Salvador harbours one of the largest Central American human immunodeﬁciency virus (HIV) epidemics, but few studies have analysed it
in depth. Here, we describe the presence of transmitted drug resistance (TDR) and HIV variants in the HIV-infected adult population in El
Salvador. Dried blood spots from 119 HIV-infected antiretroviral-naive adults attended in El Salvador were collected in 2011. The TDR was
assessed according to the list recommended by the WHO. HIV-1 variants were described using phylogeny. Pol sequences could be ampliﬁed
in 88 patients (50.6% men), with a mean age of 35 years. Almost all (96.7%) were infected with HIV through sexual practice and 58.7% were
recently diagnosed. The mean CD4+ count was 474 cells/mm3 and 43.1% and 15.5% of patients showed moderate (<500 CD4 cells) or
severe (<200) immune suppression, respectively. HIV-1 viral load was >100 000 copies/mL in 24.7% of patients and <2000 copies/mL in
9.1%. Five samples (5.7%) harboured any TDR mutation: 2.3% for nucleoside reverse transcriptase inhibitor (NRTI) and non-nucleoside
reverse transcriptase inhibitor (NNRTI), and 1.4% for protease inhibitor (PI). All showed only one TDR single-class resistance mutation:
M184I (two cases) for NRTI, K101E and K103N for NNRTI and L23I for PI. All viruses excepting one (URF_BG) belonged to subtype B. No
phylogenetic TDR networks were found. In conclusion, we report a TDR prevalence of 5.7% in El Salvador, lower than in other Central
American studies. Periodical studies are essential to monitor and prevent TDR emergence in low-income and middle-income regions. Also,
more efforts are needed to promote early diagnosis and prevention of infection in El Salvador.
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Introduction
Central America is among the regions with highest human
immunodeﬁciency virus (HIV-1) prevalence worldwide, with
1.5 million people infected by HIV [1]. The HIV prevalence
ranges from 0.3% in Mexico to 2.3% in Belize [1]. In 2009,
34 000 people were living with HIV in El Salvador, with an
estimated HIV prevalence of 0.8% in the adult population [1].
The national antiretroviral treatment (ART) programme
started to offer therapy in 2001, and began to scale-up access
in 2004. It established as a ﬁrst-line regimen the combination of
two nucleoside reverse transcriptase inhibitors (NRTI,
zidovudine or stavudine plus lamivudine) and one non-nucle-
oside reverse transcriptase inhibitor (NNRTI, nevirapine or
efavirenz). In 2010, ART coverage was 59% of the 16 000
HIV-infected people eligible for treatment [2].
Effectiveness of ART could be compromised by the
presence of transmitted HIV drug-resistance mutations
(TDR), i.e. those found in previously untreated HIV-infected
individuals, which increase the rates of virological failure [3].
Recent studies report an increasing prevalence of HIV drug
resistance in low-income and middle-income countries fol-
lowing the scaling -up of ART [4,5]. Certainly, TDR rates in
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Latin America and the Caribbean are on the rise [6]. In El
Salvador’s neighbouring countries, TDR is 7–12% [7–10]
among the HIV-infected adult population and recent studies
found a TDR prevalences of 10% in the Salvadorean
HIV-infected paediatric population [11] and of 9.4% in sex
workers and men who have sex with men [12]. However, no
studies have so far described the TDR rate among the general
HIV-infected population in El Salvador.
To prevent the widespread transmission of drug resistance
in low-income and middle-income countries, systematic pop-
ulation-based surveillance studies among untreated individuals
are crucial. For that purpose, the use of dried blood spots is a
practical and safe method of sample recollection, storage and
shipment [13,14]. In this study, promoted by the National
STD-HIV/AIDS Programme of the Health Ministry of El
Salvador, we describe the prevalence of transmitted drug
resistance and the distribution of HIV variants in the
HIV-infected adult population in El Salvador using dried blood
spots collected in December 2011.
Materials and Methods
Study cohort
The sample size was determined according to the number of
eligible patients (HIV-infected, ART-naive individuals with
detectable HIV viral load in the last sample and followed at
Salvadorean HIV/AIDS clinics) and an expected TDR rate of
9% as reported in neighbouring countries [9]. To determine
the study sample size the following formula was used,
n ¼ Z2/
N  p  q
i2ðN 1Þ þ Z2a  p  q
;
where n is the sample size, N is the population size, Z is the
value corresponding to the Gaussian distribution 1.96 for
a = 0.05, p is the expected prevalence, q is 1–p and i
represents the expected error, which is 10% for a = 0.05.
Considering 2300 eligible HIV-infected patients in El Salvador
according to the system of health monitoring and evaluation
that collects information from epidemiologically relevant
diseases in El Salvador (SUMEVE March 2010, personal
communication), we estimated the size of the study sample
to be 119 patients. The Ministry of Health requested that
patients of all health centres were chosen by random selection.
A number was assigned to each patient and new cases were
incorporated consecutively at the time of diagnosis until the
number of cases was completed. Demographic (age, gender,
origin, diagnosis date and mode of HIV infection) and clinical
(infection stage, HIV-1 viral load, CD4+ cell count) information
was collected by the physicians.
This study was part of a project approved by the Health
Ministry of El Salvador Ethics Committee and by the Hospital
Ramon y Cajal Clinical Research Ethics Committee. It was
designed to protect the rights of all subjects involved and to
maintain their conﬁdentiality. A signed informed consent was
obtained for each patient.
RNA extraction and sequencing
Dried blood spots were collected by adding two blood drops
to 903 ﬁlter paper cards (Schleicher & Schuell, Bio-Science
GmbH, Barcelona, Spain) in the Central Laboratory of the
Health Ministry of El Salvador in December 2011. Cards were
dried overnight at room temperature and stored at 20°C as
recommended [13] before they were shipped on dry ice to
the Hospital Ramon y Cajal (Madrid, Spain) for testing. Then,
blood from two dried blood spot circles per patient was
eluted in 2 mL of NucliSENS lysis buffer (BioMerieux, Madrid,
Spain) for 2 h with gentle rotation and processed to extract
RNA according to the manufacturer’s instructions using
NucliSENS EasyMAG instrumentation (BioMerieux). HIV-1
RNA was ampliﬁed by RT-PCR followed by nested PCR in
partial HIV-1 pol gene (including the protease (PR, 297
nucleotides) and/or reverse transcriptase (RT) coding regions,
775 nucleotides) using conditions based on recommendations
from the WHO [13]. The nested PCR-puriﬁed products
obtained from HIV-1 RNA extracted from dried blood spots
were sent to Macrogen (Gasan-dong, Geumchun-gu, Seoul,
Korea) for direct sequencing.
Drug resistance
The pol sequences were uploaded to the Calibrated Population
Resistance tool (http://cpr.stanford.edu/cpr.cgi) [15] to identify
TDR changes deﬁned according to the list of mutations for
TDR surveillance recommended by the WHO and described
in Bennett et al. [16]. Additional mutations considered in the
2011 International AIDS Society-USA (IAS-USA) mutation list
[17] were manually identiﬁed to increase the information
available for the clinicians about potential emergence of
resistance when facing the ﬁrst use of ART.
HIV-1 subtyping
HIV-1 subtypes and circulating recombinant forms were
identiﬁed by phylogenetic analysis of the pol sequences. At
least two representative sequences of each of the nine
subtypes and the 49 circulating recombinant forms of HIV-1
group M available at the time of analysis were taken as
references. Neighbour-joining trees were built using MEGA5
[18] under the Kimura two-parameter model, with 1000
bootstrap re-sampling. Unclassiﬁed sequences were tested for
recombination using the program RDP3 [19].
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HIV-1 clustering
To evaluate the presence of networks involving resistance
transmission, additional approximate maximum likelihood and
Bayesian phylogenetic trees (see Supplementary material,
Figures S1 and S2, respectively) were constructed. These
trees included all the pol sequences available at GenBank from
El Salvador (n = 124) and representative sequences from
neighbouring countries (Honduras, n = 28; Mexico, n = 5;
Belize, n = 5; Panama, n = 4; Costa Rica, n = 1). The nucle-
otide substitution model GTR+Γ was used in the phylogenetic
reconstruction for both methods, according to the dataset
analysis using JMODELTEST (http://darwin.uvigo.es/). The maxi-
mum likelihood tree was obtained with FASTTREE v2.1.3 (http://
www.microbesonline.org/fasttree) and using Shimodaira–
Hasegawa-like local branch support to test its robustness.
The Bayesian tree was estimated using Bayesian Markov chain
Monte Carlo inference with the program BEAST v1.6.1 (http://
beast.bio.ed.ac.uk). The Markov chain Monte Carlo chain ran
for 4 9 107 generations, sampling estimates every 10 000th
generation. The tree samples were used to generate a
maximum clade credibility tree, after a 25% burn-in, in which
the clusters’ robustness was determined by the posterior
probability.
Results
Study population
HIV-1 pol sequences could be obtained for 88 patients. They
were deposited in GenBank with numbers JX466948–
JX467035. In 17 cases, only the RT coding region (775
nucleotides) was ampliﬁed. Samples were taken in the
following hospitals: Santa Ana (11 patients), Ahuachapan
(nine patients), Salda~na (nine patients), Zacamil (eight
patients), General y de Psiquiatrıa (six patients), San Vicente
(ﬁve patients), Sonsonate (ﬁve patients), San Bartolo
(four patients), San Rafael (four patients), Maternidad
(three patients), Usulutan (three patients), Bloom (two
patients), Chalchuapa (two patients), Cojutepeque (two
patients), Sensuntepeque (two patients), Zacatecoluca
(two patients), Chalatenango (one patient) and San Miguel
(one patient). For nine patients, the corresponding data
were not available.
Table 1 shows the patients’ main demographic and clinical
characteristics at sampling time of these 88 patients. Distribu-
tion according to gender was equal, with a mean age of
35 years. In fact, 40.9% of the patients were <30 years old.
The main HIV transmission route was unprotected sexual
practice. The probable place of infection was known for 69
subjects, being in most cases (95.6%) El Salvador. Almost all
patients (96.6%) were diagnosed with HIV after 2006, and
58.7% were diagnosed in the year of sampling. The mean CD4+
count was 474 cells/mm3 and more than half of patients
showed moderate (43.1%) or severe (15.5%) immune sup-
pression (Table 1). In a quarter of patients (24.7%) the HIV-1
plasma viral load was >100 000 RNA copies/mL and in 9.1% it
was <2000 copies/mL.
Transmitted HIV drug resistance
Five out of the 88 antiretroviral-naive patients (5.7%) were
infected by HIV-1 variants carrying any drug-resistance
mutation, with resistance to RT in four cases and to protease
inhibitor (PI) in one patient. The ﬁve patients (four women and
one man, with ages between 25 and 44 years old) acquired the
HIV-1-infection by a sexual route and were infected by
subtype B. They had viral loads between 19 900 and 435 000
HIV-RNA copies/mL at time of sampling. One had an advanced
disease stage (74 CD4+ cells/mm3), and the remaining four
patients presented between 231 and 669 CD4+ cells/mm3.
Four were diagnosed in 2011 and one in 2010 in ﬁve different
Salvadorean clinical centres.
TABLE 1. Demographic and clinical characteristics of the
human immunodeﬁciency virus (HIV) -infected study
population at sampling time
Characteristic N % (95% CI)
Number of patients 88 –
Gender
Male 41 50.6 (39.9–61.2)
Female 40 49.4 (38.8–60.0)
Unknown 7 –
Mean age (years) 35.5 –
Age group (years)
<20 8 9.1 (4.7–16.9)
21–30 28 31.8 (23.0–42.1)
31–40 21 23.8 (16.2–33.7)
41–50 19 21.6 (14.3–31.3)
51–60 10 11.4 (6.3–19.7)
>60 2 2.3 (0.6–7.9)
Route of HIV infection
Sexual 85 96.6 (90.4–98.8)
Vertical 1 1.1 (0.2–6.2)
Others 2 2.3 (0.6–7.9)
Date of HIV diagnosis
1997–2000 1 1.1 (0.2–6.2)
2001–2005 2 2.3 (0.6–8.0)
2006–2010 33 37.9 (28.4–48.4)
2011 51 58.6 (48.1–68.4)
Unknown 1 –
CDC stage
A 55 68.7 (57.9–77.8)
B 11 13.7 (7.8–2.3)
C 14 17.5 (10.7–27.3)
Unknown 8 –
CD4+ count interval (cells/mm3)
≥500 24 41.4 (29.6–54.2)
200–499 25 43.1 (31.2–55.9)
<200 9 15.5 (8.4–26.9)
Unknown 30 –
Viral load interval (copies HIV-RNA/mL)
<1000 3 3.9 (1.3–10.8)
1000–10 000 15 19.5 (12.2–29.7)
10 000–100 000 40 51.9 (41.0–62.7)
>100 000 19 24.7 (16.4–35.3)
Unknown 11 –
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Regarding the drug class (Table 2), two patients (2.3%)
were infected with virus carrying NRTI-resistance mutations
(M184I in both cases). Two other patients (2.3%) presented
NNRTI-resistance mutations (K101E and K103N, respec-
tively). Finally, one patient 1.4% was infected with a virus
carrying the PI-resistance mutation L23I. All patients showed
only one TDR mutation, therefore affecting only one drug
class in all cases. Notably, neither thymidine-analogue muta-
tions nor K65R, NRTI-resistance substitutions, were found in
this study.
Other mutations at residues associated to drug resistance
Besides the substitutions mentioned before, additional
drug-resistance mutations included in the 2011 IAS-USA list
were detected, as well as minor resistance mutations to PI
(Table 3). In addition, ﬁve patients were infected with viruses
carrying substitutions not included in any mutation list but
located in positions related to NNRTI-resistance: four samples
included the K103R and one the K101Q.
HIV-1 variants’ distribution
Eighty-seven of the 88 patients (98.9%) were infected by HIV-1
subtype B viruses. Only one (SAL111) was infected with an
HIV-1 non-B variant, close to the recombinant CRF20_BG
described in Cuba [20] (Fig. 1). The recombination analysis
showed that SAL111 was a unique recombinant between
subtypes B and G (URF_BG). In addition, the maximum
likelihood tree (Fig. 1) showed four robust phylogenetic
clusters (more than two sequences) and two sequence pairs
of subtype B with 100% statistical support. These transmission
networks were conﬁrmed in the subsequent maximum
likelihood and Bayesian trees that included all the publicly
available sequences.
The four clusters included 30 patients: ten in clusters I and
II, and ﬁve in clusters III and IV, as labelled in Fig. 1. All involved
both men and women (in total, 18 men and 12 women). All but
one patient included in the clusters were infected with HIV
through a sexual route. None of the clusters involved
transmission of drug-resistance mutations.
Discussion
Monitoring TDR in low-income and middle-income countries
where ART programmes are being implemented is essential to
prevent the poorer virological outcomes associated with TDR
[3]. Rates of TDR in these regions tend to increase following
the scaling up of ART [4–6], so periodical molecular surveil-
lance studies of resistance mutations among the ART-naive
population are needed. Particularly, there is an urgent need for
TDR prevalence data in the Central and South American
regions. Here, we report the ﬁrst study of HIV-transmitted
resistance supported by the National STD-HIV/AIDS Pro-
gramme of the Health Ministry of El Salvador (Central
America) in the general, adult population.
Transmitted drug resistance in El Salvador
Rates of TDR from 10% to 17% have been reported in naive
adult subjects in Western Europe and the USA [6] but few
TDR studies have been conducted in other regions such as
Latin America. Table 4 reviews HIV drug resistance studies in
Central America and Mexico. In this region, the TDR rates
among adults ranged from 0% in Panama [21] to 12.5% in
certain areas of Mexico [22]. The variability across these values
can be the result of the restricted size of some study
populations, the target collective and the use of different
mutations lists (and/or different versions of these lists) when
calculating the TDR prevalence. For instance, TDR rate was
higher (above 12% in all cases) in studies focused on the
paediatric HIV-infected population [7,11,23], highlighting the
need for more studies assessing TDR in this population and
even of the revision of both the ﬁrst-line regimen aimed at
paediatric patients as well as the antiretroviral prophylaxis
used to prevent mother-to-child transmission.
We found a TDR rate of 5.7% in the general HIV-infected
population in El Salvador, which is included in the range found in
Central America (see above) but is lower than in the
neighbouring countries Honduras and Guatemala [9,10,24].
Recent studies in El Salvador reported a higher TDR prevalence
(although the conﬁdence intervals overlap) among female sex
workers and men who have sex with men (10.3% and 9%,
respectively) [12]. It could be explained by the higher HIV
prevalence among both high-risk groups (5% and 10%, respec-
tively) [25], than in the general, adult population (0.8%) [1]. In
addition, these collectives might have more access to ART, or
be more likely to be recent infections, factors associated with
higher TDR levels; although in this case, Murillo et al. [12]
reported recent infections in only 16% of patients. The age of
infection was unknown in our cohort, although the high rate of
immune depression suggests that patients were chronically
TABLE 2. Rates of transmitted HIV drug resistance in the
study population according to drug class
Drug class
(available sequences)
TDR rate
(95% CI)
TDR mutations
(cases)a
NRTI (88) 2.3% (0.6–7.9) M184I (2)
NNRTI (88) 2.3% (0.6–7.9) K101E (1), K103N (1)
PI (71) 1.4% (0.2–7.6) L23I (1)
Any (88) 5.7% (2.4–12.6)
TDR, transmitted drug resistance; NRTI, nucleoside reverse transcriptase
inhibitors; NNRTI, non-nucleoside reverse transcriptase inhibitors; PI, protease
inhibitors.
aAccording to the mutation list described in Bennett et al. [16].
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infected, therefore the presence of TDR was possibly under-
estimated. Moreover, in Murillo et al. [12], only 16% of patients
had a documented recent infection, so once more the two
study populations are not so widely different. However, other
reasons for the different ﬁndings cannot be ruled out, including
the limited sample size in our study.
Clinical implications of TDR on ﬁrst therapy
The prevalence of NRTI-resistance mutations was low (2.3%),
and due to the presence of the M184I substitution in isolates
from two patients. Nevertheless, treatment including lamivu-
dine or embricitabine is not contraindicated in the presence of
this mutation, because M184I increases the susceptibility to
other NRTIs and decreases HIV-1 replication. In all the study
population, zidovudine and stavudine would be active, and
>97% would be susceptible to a ﬁrst antiretroviral regimen
including the remaining NRTI. Therefore, the use of this family
as the backbone of the ﬁrst regimen is still strongly indicated in
El Salvador.
For NNRTIs, the same TDR rate was found (2.3%). Two
isolates harboured the mutations K101E and K103N in the RT
gene. Both can cause resistance to nevirapine and efavirenz,
but their low presence supports their use as third drug in the
ﬁrst-line ART regimen, as recommended by the Health
Ministry of El Salvador. However, we cannot exclude the
presence of other NRTI or NNRTI-related mutations in
sanctuary sites or not being detected by a population
sequencing that does not reveal minority variants.
We also found NNRTI-resistance substitutions excluded
from the WHO mutation list because they are common
polymorphisms: V90I (in three patients), V106I (in ﬁve
patients) and V179D (in three patients). However, they are
included in the IAS-USA list because they have been associated
with reduced NNRTI susceptibility [17]. In other patients we
found substitutions (Table 3) not included in either list
because, by themselves, they have no effect on NNRTI
efﬁcacy, but may contribute to reduced susceptibility in the
presence of other NNRTI-resistance mutations: K101Q,
V179D and K103R. Longitudinal studies to assess the virolog-
ical response in these patients are needed to evaluate the
effect of these polymorphisms in the treatment efﬁcacy.
Therefore, despite the low prevalence of major NNRTI
resistance mutations, the relatively high frequency of the
mentioned polymorphisms in the resistance positions suggest
not only that these patients whould be carefully monitored but
also that efforts should be multiplied to increase the frequency
TABLE 3. Mutations associated with antiretroviral drug resistance found in 31 isolates of the 88 human immunodeﬁciency virus
(HIV) -infected patients attended in El Salvador
Patient
WHO 2009a IAS-USA 2011b Other changesc
TDR to PI TDR to NRTI TDR to NNRTI DRM to PI DRM to NRTI DRM to NNRTI At PR At RT
SAL40 – – K103N – – K103N – –
SAL86 – – K101E – – K101E, E138K A71V –
SAL94 n.a. M184I – n.a. M184I – – –
SAL107 n.a. M184I – n.a. M184I – – –
SAL138 L23I – – – – – – –
SAL87 – – – – – V90I – –
SAL146 – – – – – V90I L10I –
SAL153 – – – – – V90I L10I –
SAL108 – – – – – V106I – K103R
SAL109 – – – – – V106I – K103R
SAL134 – – – – – V106I – –
SAL136 – – – – – V106I – –
SAL145 – – – – – V106I A71V –
SAL42 n.a. – – n.a. – V179D n.a. –
SAL118 – – – – – V179D A71T –
SAL135 – – – – – V179D – –
SAL166 n.a. – – n.a. – – n.a. K103R
SAL174 – – – – – – – K103R
SAL181 – – – – – – – K101Q
SAL18 – – – – – – A71T –
SAL85 – – – – – – A71T –
SAL91 – – – – – – I50F, I54F –
SAL95 – – – – – – L10I –
SAL112 – – – – – – L10I, I54F –
SAL114 – – – – – – A71T –
SAL142 – – – – – – L10V –
SAL144 – – – – – – A71T –
SAL149 – – – – – – L10V –
SAL150 – – – – – – L10F –
SAL165 – – – – – – L10I –
SAL172 – – – – – – L10V –
TDR, transmitted drug resistance; PI, protease inhibitors; NRTI, nucleoside reverse transcriptase inhibitors; NNRTI, non-nucleoside reverse transcriptase inhibitors; DRM,
drug-resistance mutations; PR, protease; RT, reverse transcriptase; –, no DRM was found; n.a., viral regions that could not be ampliﬁed.
aMutation list described in Bennett et al. [16].
bMutation list described in Johnson et al. [17].
cAt PR, minor resistance mutations to PI according to Johnson et al. [17]. At RT, changes in positions associated with NNRTI resistance.
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FIG. 1. Maximum likelihood tree of the 88 human immunodeﬁciency virus type 1 (HIV-1) pol sequences from naive population in El Salvador. Tree
constructed under the GTR+Γ model of nucleotide substitution using FASTTREE v2.1.3 (see Materials and methods) from a 1300-nucleotide alignment.
Sequence labels from this study are coloured in grey, other sequences are in black and labelled indicating subtype, accession number and sampling
country. The arrow points to the unique recombinant form specimen (SAL111), whose recombinant structure is shown in the diagram. The asterisks
denote nodes with 100% statistical support.
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of genotypic resistance testing before starting ART in the El
Salvador population, particularly as low genetic barrier
regimens (as NNRTI) are recommended as preferred options.
Finally, only one transmitted PI-resistance mutation (L23I)
was found. It is a rare substitution not previously reported in
the naive population in Central America (Table 4) that causes
low-level nelﬁnavir resistance only when it occurs in combi-
nation with other protease mutations [26]. This makes PI a
suitable ART class to use in ﬁrst-line treatment in those cases
with a contraindication to NNRTI, such as pregnancy, NNRTI
intolerance or pharmacological intolerances.
Late HIV diagnosis in El Salvador
Although most patients were young (40% being <30 years old)
and had been diagnosed <5 years before sampling, 58.6% also
showed moderate or severe immune depression (<500 CD4+
cells/mm3 in plasma), indicating a late HIV diagnosis in the
country. Accordingly, a previous study reported that nearly
60% of naive HIV-infected children in El Salvador had CD4 cells
counts <500 when they started ART [11]. More efforts are
needed to promote early diagnosis and prevention of infection
in El Salvador.
HIV variants in El Salvador
This work conﬁrms that HIV-1 subtype B, as in the rest of
Central America (Table 4), is the prevalent variant in El Salvador,
accounting for almost 99% of cases. Only one infection with
HIV-1 non-B variants was reported, caused by a unique
recombinant URF_BG close to the BG recombinants ﬁrst
described in Cuba [20]. This patient was probably infected with
HIV through a heterosexual relationship with a lorry driver.
Our study highlights that blood sampling on ﬁlter papers
(dried blood spots) is an inexpensive and practical alternative
to plasma for antiretroviral treatment monitoring in countries
with limited resources, especially when samples need to be
analysed in specialized laboratories abroad because of a lack of
resources and/or material [14].
The sample size was limited by the high rate of failures when
amplifying RNA from dried blood spots (31/119), especially for
the protease coding region (48/119). Some of these dried blood
spot samples were accidentally kept at room temperature
instead of at20°C as planned. Another limitation was the lack
of more speciﬁc data about the infection route. In addition,
although patients were chosen at random, the different HIV-1
prevalence rates in the areas where the clinics were locatedmay
affect the resistance results. Finally, the fact that most patients
were chronically infected with HIV can make the comparison of
TDR results with cohorts consisting of recently infected patients
difﬁcult, although it is a representative sample of the naive
HIV-infected population living in El Salvador.T
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In conclusion, in this work we report a moderate TDR
rate in El Salvador, Central America. Our results support
the adequacy of the Salvadorean ART guidelines. In all cases
the mutations affected only one antiretroviral class and we
found no transmission network involving TDR. However,
periodic surveillance studies are essential to monitor and
prevent the emergence of HIV drug-resistance mutations
(especially to NNRTI class) in low-income and mid-
dle-income regions.
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